Clinical trials: Cardiovascular Risk Assesment
Cardiovascular Morbidity, Cardiovascular Risk Assesment
A Hospital-Based Registry of Preventive Cardiology Clinics
More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes.
- Conditions
- Cardiovascular Morbidity, Cardiovascular Risk Assesment, Primary Prevention CVD
- Trial name
- PREVENT-CARD (NCT06503341)
- Testing
- Cardiovascular risk assesment
- Where
- Pakistan
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Diabetic Patients With/Without Atherosclerotic Diseases
Cardiovascular Risk Assesment in Diabetic Patients Via Lens Autofluorecscence Detection
The rate of lens autofluorescence will be compared in diabetic and non diabetic patients with/without atherosclerotic vascular diseases to evaluate if it is associated with the risk of cardiovascular diseases.
- Trial name
- CRADILA (NCT02947555)
- Testing
- Non interventional
- Where
- Hungary
- Volunteers
- 420 people
- Sponsor
- Dr. Gergő Molnár
Hypertrophic Cardiomyopathy
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes.
- Trial name
- NCT04402268
- Testing
- Cardioverter-defibrillator
- Where
- Poland
- Volunteers
- 252 people
- Sponsor
- Poznan University of Medical Sciences
Dyslipidemias, Hyperlipidemias
PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT
Dyslipidemias are a major risk factor for the onset of cardiovascular disease, while early diagnosis and appropriate treatment approaches significantly reduce cardiovascular morbidity and mortality.
- Conditions
- Dyslipidemias, Hyperlipidemias, Risk Factor, Cardiovascular, Quality of Life
- Trial name
- PLATINUM (NCT03329729)
- Testing
- Rosuvastatin
- Where
- Greece
- Volunteers
- 4,700 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Obesity
Association of Triglyceride-glucose Index With Cardiac Hemodynamics
1) To estimate the prevelance of IR in obese patients based on TYG index . 2) To screen early cardiovascular abnormalities in obese asymptomatic patients using conventional echocardiography and electrocardiogram .
- Trial name
- NCT05702112
- Volunteers
- 100 people
- Sponsor
- Assiut University